Pathology of nonalcoholic steatohepatitis.

Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized form of chronic liver injury. Nonalcoholic steatohepatitis (NASH) is the term applied to the microscopically-defined subset of NAFLD with known progression to cirrhosis and the complications that may be associated, including metabolic imbalances, liver failure and hepatocellular carcinoma. NASH is also being considered as a significant precursor of end-stage liver disease, ''cryptogenic cirrhosis'', in which the histologic features of the initial liver disease can no longer be appreciated. Because of the increasing prevalence and the known significance of this form of liver disease, current investigations are focused on discerning the clinical features of susceptible patients, the histopathologic findings that characterize the entity and serve as markers of progression, pathogenetic mechanisms that result in triglyceride accumulation, liver injury and fibrosis, and ultimately, treatment options.

[1]  J. Parks,et al.  Mitochondrial abnormalities in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.

[2]  L. Krugner-Higby,et al.  Mitochondria in nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[3]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[4]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[5]  J. Ludwig,et al.  The nomenclature of chronic active hepatitis: an obituary. , 1993, Gastroenterology.

[6]  P. Scheuer,et al.  Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.

[7]  S. Caldwell,et al.  Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.

[8]  E. Brunt.  Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.

[9]  F. Brancati,et al.  Nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[10]  G. Gores,et al.  Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. , 2003, Gastroenterology.

[11]  A. Burt,et al.  Diagnosis and interpretation of steatosis and steatohepatitis. , 1998, Seminars in diagnostic pathology.

[12]  P. Scheuer,et al.  The nomenclature of chronic hepatitis: time for a change. , 1995, Journal of hepatology.

[13]  M. Weltman,et al.  HFE mutations, hepatic iron, and fibrosis: Ethnic‐specific association of NASH with C282Y but not with fibrotic severity , 2002, Hepatology.

[14]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[15]  E. Brunt.  Alcoholic and nonalcoholic steatohepatitis. , 2002, Clinics in liver disease.

[16]  G. Farrell.  Drugs and Steatohepatitis , 2002, Seminars in liver disease.

[17]  T. Saibara.  “Insufficient” leptin production for the fat mass: a risk factor for nonalcoholic steatohepatitis in obese patients? , 2003, Journal of Gastroenterology.

[18]  G. Marchesini,et al.  Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.

[19]  R. Stravitz,et al.  Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome , 2003, American Journal of Gastroenterology.

[20]  J. Hoofnagle,et al.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.

[21]  O. Cummings,et al.  160 Design and validation of a histologic scoring system for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) , 2003 .

[22]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[23]  Z. Younossi,et al.  Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. , 2001, Liver.

[24]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[25]  P. Giral,et al.  Liver fibrosis in overweight patients. , 2000, Gastroenterology.

[26]  A. Sanyal,et al.  AGA technical review on nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[27]  E. Brunt,et al.  Pathology of steatohepatitis. , 2002, Best practice & research. Clinical gastroenterology.

[28]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[29]  S. Caldwell,et al.  The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis , 2004, Hepatology.

[30]  G. Farrell.  Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region? , 2003, Journal of gastroenterology and hepatology.

[31]  R. Deutsch,et al.  Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. , 2003, The Journal of pediatrics.

[32]  B. Neuschwander‐Tetri,et al.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.

[33]  B. Neuschwander‐Tetri,et al.  Concurrence of Histologic Features of Steatohepatitis with Other Forms of Chronic Liver Disease , 2003, Modern Pathology.

[34]  K. Ishak,et al.  Chronic hepatitis: morphology and nomenclature. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[35]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[36]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[37]  K. Lindor,et al.  Treatment of non-alcoholic steatohepatitis. , 2002, Best practice & research. Clinical gastroenterology.

[38]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[39]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[40]  S. Seki,et al.  In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. , 2002, Journal of hepatology.

[41]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[42]  P. D. James,et al.  Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. , 2001, Journal of hepatology.

[43]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[44]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[45]  J. Ludwig,et al.  Two cases from the spectrum of nonalcoholic steatohepatitis. , 1995, Journal of clinical gastroenterology.

[46]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[47]  J. Ludwig,et al.  Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. , 2002, Journal of hepatology.